Read the question beside the result
These are the sources cited on the site. Each has a job, and each leaves some questions unanswered.
Hormone responses and the pairing idea
These papers explain why the ingredients attracted interest. Blood measurements and animal findings need their setting beside them to stay useful.
Teichman and colleagues studied CJC-1295 with DAC in healthy adults in 2006. They measured growth hormone and the related growth factor IGF-1, both elevated for days. That experiment didn’t show a gain in sleep quality or exercise recovery.
Ionescu and Frohman followed CJC-1295 with DAC and hormone pulses in healthy men in 2006. The pulses continued, but the low level between them rose. Gobburu and colleagues studied intravenous ipamorelin in healthy men in 1999. Its short blood profile belongs to that route.
Raun and colleagues’ 1998 selectivity experiments included pigs and their stress-hormone responses. Bowers and colleagues combined related releasing signals in men in 1990. Neither paper establishes the safety or daily benefits of the fixed blend.
A paper’s title gets you to the door. Its participants and outcome tell you where you’ve arrived.
A practical outcome and some safety questions
A plausible explanation doesn’t settle whether a treatment helps. These sources bring the discussion back to outcomes and unwanted effects.
Beck and colleagues’ 2014 bowel-surgery trial tested intravenous ipamorelin against placebo. It asked when patients could tolerate a meal. The main comparison wasn’t statistically significant, so the study didn’t establish a benefit.
Sigalos and colleagues reviewed growth hormone-releasing drugs in 2018. They highlighted blood sugar, reduced response to insulin and limited longer-term safety evidence. This is evidence about the drug class, rather than a safety trial of the fixed blend.
An unanswered question is part of the account. A source list can help keep it visible.
Names, safety concerns and approval
FDA documents answer questions about the exact ingredients and regulatory status. They don’t turn prescription access into evidence that a preparation works.
The FDA’s 2024 CJC-1295 assessment separates the DAC and no-DAC forms and reviews safety concerns. The FDA’s 2024 ipamorelin assessment reviews the human studies and gaps in safety evidence for injections under the skin.
On the FDA’s safety page, whose content date is April 22, 2026, CJC-1295 and ipamorelin acetate appear among withdrawn nominations. For 503B outsourcing facilities, FDA also keeps ipamorelin acetate in Category 2. Taking back a nomination doesn’t clear an ingredient for compounding. The page doesn’t date individual withdrawals.
Compounding leaves a medicine without FDA approval, as the agency’s explanation makes clear. The comparison returns these sources to the ordinary question of what was actually shown.